ICU Medical, Inc. (NASDAQ:ICUI) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of ICU Medical, Inc. (NASDAQ:ICUI) have received a consensus recommendation of “Moderate Buy” from the four analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $199.67.

A number of research analysts recently commented on the stock. Raymond James increased their target price on shares of ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a research report on Thursday, September 12th. Jefferies Financial Group raised shares of ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 target price on the stock in a research report on Wednesday, December 11th. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a research report on Wednesday, November 13th. StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Wednesday, November 20th. Finally, KeyCorp raised their price objective on shares of ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 13th.

Insider Transactions at ICU Medical

In other news, CEO Vivek Jain sold 12,000 shares of the firm’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $162.91, for a total value of $1,954,920.00. Following the completion of the sale, the chief executive officer now owns 104,593 shares in the company, valued at approximately $17,039,245.63. This trade represents a 10.29 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Christian B. Voigtlander sold 1,962 shares of the firm’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $169.08, for a total transaction of $331,734.96. The disclosure for this sale can be found here. In the last quarter, insiders sold 40,364 shares of company stock worth $6,869,878. Company insiders own 6.70% of the company’s stock.

Institutional Trading of ICU Medical

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. State Street Corp lifted its stake in shares of ICU Medical by 9.3% in the third quarter. State Street Corp now owns 907,607 shares of the medical instruments supplier’s stock valued at $165,384,000 after purchasing an additional 77,506 shares during the period. Geode Capital Management LLC lifted its stake in shares of ICU Medical by 9.6% in the third quarter. Geode Capital Management LLC now owns 546,954 shares of the medical instruments supplier’s stock valued at $99,687,000 after purchasing an additional 48,106 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of ICU Medical by 21.7% in the second quarter. Dimensional Fund Advisors LP now owns 311,542 shares of the medical instruments supplier’s stock valued at $36,996,000 after purchasing an additional 55,588 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of ICU Medical by 10.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 301,107 shares of the medical instruments supplier’s stock valued at $54,868,000 after purchasing an additional 27,927 shares during the period. Finally, WCM Investment Management LLC lifted its stake in shares of ICU Medical by 1.3% in the third quarter. WCM Investment Management LLC now owns 259,481 shares of the medical instruments supplier’s stock valued at $45,272,000 after purchasing an additional 3,407 shares during the period. Institutional investors and hedge funds own 96.10% of the company’s stock.

ICU Medical Trading Down 1.2 %

NASDAQ ICUI opened at $157.17 on Friday. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03. The firm’s fifty day moving average price is $170.34 and its 200 day moving average price is $152.40. The company has a market capitalization of $3.85 billion, a price-to-earnings ratio of -34.39 and a beta of 0.62. ICU Medical has a 12 month low of $86.80 and a 12 month high of $196.26.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.